 |
471 Diseases |  |
207 Trials |
|
207 Trials |  |
10577 News |  |
| «12...5354555657585960616263...132133» |
- letrozole / Generic mfg., tamoxifen / Generic mfg., everolimus / Generic mfg.
[VIRTUAL] Long-term results and bone-protective effect of everolimus added to letrozole and ovarian function suppression for premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: an updated analysis of the LEO study () - Mar 9, 2021 - Abstract #ESMOBC2021ESMO_BC_258;
P2
EVE plus LET with ovarian-suppression prolonged PFS in patients with baseline visceral or bone metastases and offered bone-protective effect in the overall study population. However, these clinical benefits were not translated into an OS benefit.
- |||| everolimus / Generic mfg., lenvatinib / Generic mfg.
Clinical: .@montypal detailed the phase 2 trial of lenvatinib at 2 starting doses plus everolimus to treat patients with renal cell carcinoma. | @cityofhope https://t.co/j9YZahvgVU (Twitter) - Mar 9, 2021
- | everolimus / Generic mfg.
Journal: Peroxisomal abnormalities and catalase deficiency in Hutchinson-Gilford Progeria Syndrome. (Pubmed Central) - Mar 9, 2021
Interestingly, RAD001 treatment significantly upregulated catalase activity in HGPS cells. Our study presents the first characterization of peroxisomal function in HGPS and provides new insights into the cellular aspects of HGPS and the ongoing clinical trial.
- | everolimus / Generic mfg.
Journal: Cyclodextrin inclusion complex inhibits circulating galectin-3 and FGF-7 and affects the reproductive integrity and mobility of Caco-2 cells. (Pubmed Central) - Mar 9, 2021
In this study, we investigated the effect of β-cyclodextrin:everolimus:FGF-7 inclusion complex (Complex) on Caco-2 cell migration, cell motility and colony formation...This confirms Swiss Target Prediction result that predicted β-CD could target FGF. These findings advance the understanding of the biological effects of the Complex which reduced cell migration, cell motility and colony formation and it is possibly due to inhibiting circulating proteins such as; Gal-3 and FGF-7.
- || Campath (alemtuzumab) / Sanofi
Review, Journal: Risk of infection associated with targeted therapies for solid organ and hematological malignancies. (Pubmed Central) - Mar 9, 2021
Venetoclax is associated with cytopenias, respiratory infections, and fever and neutropenia...Alemtuzumab is associated with profound and long-lasting immunosuppression; screening is recommended for latent infections and prevention strategies against CMV, herpesvirus, and Pneumocystis infections. Checkpoint inhibitors (CIs) may cause immune-related adverse events for which prolonged treatment with corticosteroids is needed: prophylaxis against Pneumocystis is recommended.
- || everolimus / Generic mfg.
Clinical, Journal: A survey of the European Reference Network EpiCARE on clinical practice for selected rare epilepsies. (Pubmed Central) - Mar 9, 2021
Available, widely used targeted therapies included everolimus in TSC and immunosuppressive therapies in autoimmune encephalitis...The survey summarizes the current clinical practice for selected rare epilepsies in tertiary European epilepsy centers and demonstrates consistency as well as heterogeneity in the treatment, underscoring the need for controlled trials and recommendations. The survey also provides estimates for potential participants of clinical trials recruited via EpiCARE, emphasizing the great potential of Reference Networks for future studies to evaluate new targeted therapies and to identify novel biomarkers.
- | everolimus / Generic mfg.
Journal: Trends in survival and treatment of SEGA: National Cancer Database Analysis. (Pubmed Central) - Mar 6, 2021
Surgical resection was performed in older patients with larger tumors (> 20 mm) as a primary mode of treatment, without chemoradiotherapy. Expectedly, rates of surgical resection were found to have decreased since 2011, after FDA approval of everolimus for SEGA treatment.
- | Journal: The Effects of Immunosuppressive Treatment during Pregnancy on the Levels of Potassium, Iron, Chromium, Zinc, Aluminum, Sodium and Molybdenum in Hard Tissues of Female Rats and Their Offspring. (Pubmed Central) - Mar 5, 2021
The therapy based on cyclosporine A, everolimus and prednisone led to a decline in the levels of iron in bone, zinc in teeth, and molybdenum in the bone and teeth of mothers, while in the offspring, it caused a decline of bone potassium, with a decrease in iron and increase of molybdenum in teeth. Moreover, the regimen caused an increase in aluminum and chromium in the teeth and aluminum in the bones of the offspring, and consequently, it seems to be the therapy with the most negative impact on the mineral metabolism in hard tissues.
- |||| Piqray (alpelisib) / Novartis
Clinical: Great case @DrSteveMartin have a similar squamous cell non smoker with L858R+PIK3CA responding to Osi and everolimus. (Everolimus due to cost). My vote would be for Osi+alpelisib although L858R is emerging as a notorious one and I am beginning to use more RELAY or Daco in these (Twitter) - Mar 3, 2021
- || belzutifan (MK-6482) / Merck (MSD)
Lenvatinib + everolimus followed by belzutifan when available. Tivozinib may soon be an option too @montypal @TiansterZhang @DrVaishampayan (Twitter) - Mar 3, 2021
- || everolimus / Generic mfg.
Enrollment change: Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus (clinicaltrials.gov) - Mar 3, 2021
P=N/A, N=30, Recruiting, Sponsor: University of Kansas Medical Center
Moreover, the regimen caused an increase in aluminum and chromium in the teeth and aluminum in the bones of the offspring, and consequently, it seems to be the therapy with the most negative impact on the mineral metabolism in hard tissues. N=20 --> 30
- || Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Clinical, Journal: c-MET as a Potential Resistance Mechanism to Everolimus in Breast Cancer: From a Case Report to Patient Cohort Analysis. (Pubmed Central) - Mar 3, 2021
N=20 --> 30 c-MET could play a role in the resistance to everolimus and its inhibition should be evaluated in breast cancer.
- | Revlimid (lenalidomide) / BMS, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: Waldenström Macroglobulinemia: 2020 Update on Diagnosis, Risk Stratification, and Management. (Pubmed Central) - Mar 3, 2021
Bortezomib, fludarabine, thalidomide, everolimus, Bruton Tyrosine Kinase inhibitors, carfilzomib, lenalidomide, and bendamustine have all been shown to have activity in relapsed WM. Given WM's natural history, reduction of therapy toxicity is an important part of treatment selection.
- paclitaxel / Generic mfg., fulvestrant / Generic mfg.
[VIRTUAL] Physician survey in the treatment of HR+/HER2− metastatic breast cancer in Egypt () - Mar 2, 2021 - Abstract #SGBCC2021SG_BCC_147;
The most preferred treatments reported by physicians for second‐line therapy included a different endocrine combination therapy (58.8%). For subsequent line treatment, the most preferred treatments were CT monotherapy.
- ||| Trial completion, Biopsy, Post-transplantation: Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens (clinicaltrials.gov) - Mar 2, 2021
P=N/A, N=88, Completed, Sponsor: Northwestern University
For subsequent line treatment, the most preferred treatments were CT monotherapy. Active, not recruiting --> Completed
- |||| Herceptin (trastuzumab) / Roche
Clinical: Check out our FIH trial of letrozole + everolimus + trastuzumab in 32 pts with HR+/HER2+ advanced cancers selected as highlight in current issue of @CCR_AACR! Congratulations to @FilipJankuMD and wonderful team @MDAndersonNews @DavidHongMD @VivekSubbiah https://t.co/Mti69NKtrp (Twitter) - Mar 2, 2021
- || sirolimus / Generic mfg., cyclosporine / Generic mfg.
Clinical, Journal: Comparison of serum monocide chemoattractant protein levels with immunosuppressive therapy protocols in patients with renal transplantation. (Pubmed Central) - Mar 2, 2021
7, Ref. 45).
- || Xofigo (radium Ra-223 dichloride) / Bayer
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer (clinicaltrials.gov) - Mar 2, 2021
P2, N=283, Active, not recruiting, Sponsor: Bayer
45). Trial completion date: Mar 2021 --> Jun 2021 | Trial primary completion date: Mar 2021 --> Jun 2021
- || sirolimus / Generic mfg.
Review, Journal: The Putative Role of mTOR Inhibitors in Non-tuberous Sclerosis Complex-Related Epilepsy. (Pubmed Central) - Mar 2, 2021
Mutations in mTOR or the mTOR pathway have been found in hemimegalencephaly (HME) and focal cortical dysplasias (FCDs), both of which are highly correlated with medically refractory epilepsy. Given the evidence to date, a logical next step is to investigate the role of mTOR inhibitors in the treatment of children with medically refractory non-TSC epilepsy, particularly those children who have also failed resective surgery.
- || everolimus / Generic mfg.
Clinical, Journal: Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China. (Pubmed Central) - Mar 2, 2021
P=N/A
In the advanced setting, the choices of palliative ET regimens were diverse, yet aromatase inhibitor (AI) monotherapy was still the overall mainstay of ET; in contrast, patients were less accessible to everolimus plus AI regimen in this population...Patients who received multi-lines of ET experienced successive shorter durations following each line of therapy. This real-life data provides a solid overview of ET for HR+ ABC from China, indicating unmet need for treatment options that improve the effectiveness of endocrine therapy.
- || everolimus / Generic mfg.
Clinical, Journal: A randomized double-blind controlled trial of everolimus in individuals with PTEN mutations: Study design and statistical considerations. (Pubmed Central) - Mar 2, 2021
We predicted that the rate of adverse events would be no more than 10% higher in the everolimus group compared to placebo, and overall severity of side effects would be minimal. We also expected that individuals receiving everolimus would show more improvement, relative to those taking placebo, on the composite neurocognitive index.
- | Trial completion date, Trial primary completion date, Stroma: DSC-BROMS-1: Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT (clinicaltrials.gov) - Mar 1, 2021
P1/2, N=50, Not yet recruiting, Sponsor: Mats Remberger
We also expected that individuals receiving everolimus would show more improvement, relative to those taking placebo, on the composite neurocognitive index. Trial completion date: Dec 2027 --> May 2028 | Trial primary completion date: Dec 2022 --> May 2023
- | Torisel (temsirolimus) / Pfizer
Journal: Network determinants of cardiovascular calcification and repositioned drug treatments. (Pubmed Central) - Feb 26, 2021
An integrated network analytical approach identified novel mediators of ectopic cardiovascular calcification and biologically plausible candidate drugs that could be repurposed to target calcification. This methodological framework for drug repurposing has broad applicability to other diseases.
- |||| Eligard (leuprolide acetate) / TOLMAR, Astellas, Sanofi
Clinical: Leuprorelin Combined With Letrozole ± Everolimus in Ovarian-Suppressed Premenopausal Women With HR+ HER2− Metastatic #BreastCancer. Comment by Reshma L. Mahtani DO #bcsm @DrReshmaMahtani https://t.co/9RZt2q8xJ3 (Twitter) - Feb 25, 2021
- ||| Campath (alemtuzumab) / Sanofi
Trial completion, Trial completion date, Trial primary completion date: Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath (clinicaltrials.gov) - Feb 25, 2021
P4, N=55, Completed, Sponsor: University of Toledo Health Science Campus
This methodological framework for drug repurposing has broad applicability to other diseases. Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Jul 2020 | Trial primary completion date: Dec 2020 --> Jul 2020
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, Kineret (anakinra) / SOBI
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases: NCI-2018-01842: Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers (clinicaltrials.gov) - Feb 25, 2021
P1, N=57, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Jul 2020 | Trial primary completion date: Dec 2020 --> Jul 2020 Active, not recruiting --> Completed | Trial completion date: Jun 2020 --> Feb 2021 | Trial primary completion date: Jun 2020 --> Feb 2021
- || letrozole / Generic mfg., everolimus / Generic mfg.
If ER positive I try to stay off chemo for as long as practical... so, meg/tam then letrozole/everolimus... It can get a person years before seeing more toxic therapy. #GynOncChat (Twitter) - Feb 24, 2021
- || letrozole / Generic mfg., everolimus / Generic mfg.
I use this regimen quite a bit as well in addition to everolimus and letrozole. (and sometimes both sequentially). #gyncsm #gynoncchat (Twitter) - Feb 24, 2021
- ||||| Sutent (sunitinib) / Pfizer
Biomarker, Clinical: Armstrong et al identify several poor prognosis #angiokines and immunomodulatory #chemokines during treatment with #sunitinib or #everolimus in patients with non-clear cell renal cell carcinomas. #biomarkers @AarmstrongDuke @DrVaishampayan https://t.co/v5zFZJLNbm (Twitter) - Feb 24, 2021
- |||| everolimus / Generic mfg.
Clinical: Efficacy and Safety Data of Everolimus for #NeuroendocrineTumors. https://t.co/wgv1Nwfw9r @DanengLi @Pharmacy_Times @cityofhope (Twitter) - Feb 23, 2021
- | Journal: The role of PI3K/Akt/mTOR signaling in dose-dependent biphasic effects of glycine on vascular development. (Pubmed Central) - Feb 23, 2021
Treatment with inhibitors of mTORC1 (rapamycin and everolimus), mTORC1/mTORC2 (KU0063794), PI3K (LY29400), and Akt (Akt inhibitor) decreased the development of intersegmental vessels (ISVs)...Our results suggest that PI3K/Akt/mTOR signaling may interact with dose-dependent biphasic effects of exogenous glycine on in vivo angiogenesis. mTOR signaling is a key target for cancer therapy, thus, the combining mTOR inhibitors with glycine may be a potential approach for controlling angiogenesis.
- | Kisqali (ribociclib) / Novartis
Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors (clinicaltrials.gov) - Feb 23, 2021
P2, N=21, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
mTOR signaling is a key target for cancer therapy, thus, the combining mTOR inhibitors with glycine may be a potential approach for controlling angiogenesis. Trial completion date: Feb 2021 --> Feb 2022 | Trial primary completion date: Feb 2021 --> Feb 2022
- || Irene (pyrotinib) / Jiangsu Hengrui Medicine
Clinical, Review, Journal: Efficacy of second-line treatments for patients with advanced human epidermal growth factor receptor 2 positive breast cancer after trastuzumab-based treatment: a systematic review and bayesian network analysis. (Pubmed Central) - Feb 23, 2021
Our work comprehensively summarized and analyzed current available RCT-based evidence of the second-line treatments for trastuzumab-treated, HER2-positive, advanced breast cancer. These results provide clinicians and oncologists meaningful references for clinical drug administration and the development of novel effective therapies.
- | Tagrisso (osimertinib) / AstraZeneca
Trial completion date, Trial primary completion date: Implantable Microdevice In Primary Brain Tumors (clinicaltrials.gov) - Feb 23, 2021
P1, N=12, Recruiting, Sponsor: Oliver Jonas
These results provide clinicians and oncologists meaningful references for clinical drug administration and the development of novel effective therapies. Trial completion date: Feb 2021 --> Feb 2022 | Trial primary completion date: Jan 2021 --> Sep 2021
- ||||| everolimus / Generic mfg., lenvatinib / Generic mfg.
These results were from an exploratory analysis of the trial, which examined lenvatinib at 2 different starting doses plus a set dose of everolimus following prior VEGF inhibitor therapy. @montypal @cityofhope @ASCO #GU21 https://t.co/qDKdZDClfL (Twitter) - Feb 21, 2021
- | everolimus / Generic mfg.
Trial completion date, Trial primary completion date: UNIRAD: Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy (clinicaltrials.gov) - Feb 21, 2021
P3, N=1279, Active, not recruiting, Sponsor: UNICANCER
Trial completion date: Feb 2021 --> Feb 2022 | Trial primary completion date: Jan 2021 --> Sep 2021 Trial completion date: Apr 2025 --> Jun 2030 | Trial primary completion date: Dec 2020 --> Jun 2020
- | serabelisib (MLN1117) / Takeda
Trial completion date, Metastases: MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma (clinicaltrials.gov) - Feb 21, 2021
P2, N=96, Completed, Sponsor: Millennium Pharmaceuticals, Inc.
Trial completion date: Apr 2025 --> Jun 2030 | Trial primary completion date: Dec 2020 --> Jun 2020 Trial completion date: Mar 2020 --> Oct 2020
- | everolimus / Generic mfg.
Trial completion date, Trial primary completion date: Analysis of Circulating Tumor Markers in the Blood (ALCINA) (clinicaltrials.gov) - Feb 21, 2021
P=N/A, N=760, Recruiting, Sponsor: Institut Curie
Trial completion date: Mar 2020 --> Oct 2020 Trial completion date: Jul 2022 --> Jan 2025 | Trial primary completion date: Jan 2021 --> Jul 2023
- || Lumakras (sotorasib) / Amgen
Enrollment change, Trial primary completion date, Combination therapy, Monotherapy, IO biomarker, Metastases: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Feb 21, 2021
P1b, N=1003, Recruiting, Sponsor: Amgen
Trial completion date: Jul 2022 --> Jan 2025 | Trial primary completion date: Jan 2021 --> Jul 2023 N=520 --> 1003 | Trial primary completion date: Jul 2027 --> May 2023
- | metformin / Generic mfg., everolimus / Generic mfg.
Journal: Hypoxia and hypoxia-inducible factors promote the development of neointimal hyperplasia in arteriovenous fistula. (Pubmed Central) - Feb 21, 2021
We used the same drugs on a mouse model of AVF and show that direct or indirect inhibition of the hypoxia-inducible factors (HIFs) help decrease excessive venous thickness. Hypoxia and HIFs can be targets of therapeutic drugs to prevent excessive venous thickness in patients undergoing AVF surgical creation.
- | Preclinical, Journal: WNK2 Inhibits Autophagic Flux in Human Glioblastoma Cell Line. (Pubmed Central) - Feb 20, 2021
The WNK2-methylated human glioblastoma cell line A172 WT (wild type) was compared to transfected clones A172 EV (empty vector), and A172 WNK2 (WNK2 overexpression) for the evaluation of autophagy using an inhibitor (bafilomycin A1-baf A1) and an inducer (everolimus) of autophagic flux...The mTOR pathway was also evaluated under the same conditions, and the observed results suggest that the inhibition of autophagy mediated by WNK2 occurs through a mTOR-independent pathway. In conclusion, the evaluation of the autophagic process demonstrated that WNK2 inhibits the autophagic flux in glioblastoma cell line.
- || Torisel (temsirolimus) / Pfizer, Sutent (sunitinib) / Pfizer
Clinical, Journal: Different immunological effects of the molecular targeted agents sunitinib, everolimus and temsirolimus in patients with renal cell carcinoma. (Pubmed Central) - Feb 20, 2021
In conclusion, although everolimus and temsirolimus are mTOR inhibitors, their effects on overall T‑cell functions are very different. Therefore, although it may increase the risk of immune‑related toxicity, temsirolimus is expected to offer the best outcome when combined with other immunomodulators for the development of cancer immunotherapy.
- | everolimus / Generic mfg., sirolimus / Generic mfg.
Journal: Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells. (Pubmed Central) - Feb 20, 2021
In conclusion, the addition of SFN to the long-term everolimus application inhibits resistance development in bladder cancer cells in vitro. Therefore, sulforaphane may hold potential for treating bladder carcinoma in patients with resistance to an mTOR inhibitor.
- | Bylantra (devimistat) / Rafael Pharma, Ono Pharma
Journal: Neural signaling modulates metabolism of gastric cancer. (Pubmed Central) - Feb 20, 2021
We demonstrate the efficacy of nerve-cancer metabolism therapy by intratumoral injection of BoNT-A (SNAP25 inhibitor) with systemic administration of RAD001 and CPI-613 but not cytotoxic drugs on overall survival in mice and show the feasibility in patients. These findings point to the importance of neural signaling in modulating the tumor metabolism and provide a rational basis for clinical translation of the potential strategy for gastric cancer.
- || Kisqali (ribociclib) / Novartis
I wonder if a really low dose of everolimus + normal dose ribociclib with ET would have been a better strategy. Maybe an extra arm on NATALEE? (Twitter) - Feb 19, 2021
- ||| everolimus / Generic mfg.
Everolimus is done and dusted drug . It came on scene around 10 years back and was hyped Now it is time to say good bye. Same may happen to CDK inhibitors after next ten years . Circle of phamra . (Twitter) - Feb 19, 2021
- |||| everolimus / Generic mfg.
Clinical: The abstract of the first @myESMO Virtual Plenary that took place today is now available here: Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer https://t.co/2BtbqWdDrX #bcsm @thomas_bachelot @FAndreMD @GroupeUNICANCER (Twitter) - Feb 19, 2021
- || everolimus / Generic mfg.
Very difficult to tolerate Everolimus for a long period of time (Twitter) - Feb 19, 2021
- ||||| Verzenio (abemaciclib) / Eli Lilly
Clinical: UNIRAD study: Addition of everolimus to ET does not improve IDFS in adjuvant therapy for pts with high risk HR+/HER2- early breast cancer. Not the same "high risk" definition as MONARCHE, where abemaciclib did show improvement in IDDS @OncoAlert @myESMO #bcsm (Twitter) - Feb 19, 2021
- ||||| everolimus / Generic mfg.
Clinical: No role for adjuvant everolimus in ER+ breast cancer. https://t.co/ck6R78sEu3 (Twitter) - Feb 19, 2021